公开(公告)号：US20010055787A1

公开(公告)日：2001-12-27

申请号：US09812986

申请日：2001-03-20

Inventor： Leonid Heifets ,  Tracy Sanchez

IPC: C12Q001/18 ,  C12N001/38

CPC classification number: C12Q1/18 ,  C12N1/20 ,  C12Q1/045

Abstract: A novel agar medium for the isolation, sub-cultivation, and indirect or direct drug-susceptibility testing of Mycobacterium tuberculosis is disclosed. Also disclosed are methods of isolating and growing Mycobacterium tuberculosis and methods of drug-resistance screening using the agar medium of the invention.

Abstract translation: 公开了用于结核分枝杆菌的分离，亚培养和间接或直接药物敏感性试验的新型琼脂培养基。 还公开了使用本发明的琼脂培养基分离和生长结核分枝杆菌的方法和耐药筛选方法。

公开(公告)号：US20010044129A1

公开(公告)日：2001-11-22

申请号：US09804774

申请日：2001-03-13

Inventor： Jian Ling ,  Steven D. Weitman ,  Michael A. Miller

IPC: C12Q001/18

CPC classification number: G01N21/65 ,  Y10T436/24

Abstract: A method of using Raman imaging microscopy to evaluate drug actions in living cells is disclosed. Specifically the invention describes the methods of using Raman imaging microscopy to detect drug uptake, distribution, binding, and metabolism in a single cell, and to study drug pharmacokinetics at the cellular level. The method involves measuring the Raman image of both the drug and the cell. Control images and post-treatment images of the cell were studied. Ratio images were calculated and the requisite information was obtained from a study of the intensity of the bright areas in the ratio images.

Abstract translation: 公开了使用拉曼成像显微镜评估活细胞药物作用的方法。 具体地，本发明描述了使用拉曼成像显微镜检测单细胞中药物摄取，分布，结合和代谢的方法，以及研究细胞水平的药物药代动力学。 该方法涉及测量药物和细胞的拉曼图像。 研究了细胞的图像和后处理图像。 计算比率图像，并从比较图像中亮区强度的研究中获得必要的信息。

公开(公告)号：US20040248773A1

公开(公告)日：2004-12-09

申请号：US10742541

申请日：2003-12-19

Inventor： Matthew M. Tanzer ,  Jeffrey R. Shuster ,  Todd M. DeZwaan ,  Sheryl A. Frank ,  Maria V. Montenegro-Chamorro ,  Ryan W. Heiniger ,  Amy S. Covington ,  Lisbeth Hamer ,  Kiichi Adachi ,  Sze-Chung Lo ,  Blaise A. Darveaux ,  Sanjoy K. Mahanty ,  Huaqin Pan ,  Rex Tarpey

IPC: A61K038/00 ,  C12Q001/18

CPC classification number: C12Q1/18 ,  G01N2333/906 ,  G01N2500/02 ,  G01N2500/04

Abstract: The present inventors have discovered that pyrroline-5-carboxylate reductase is essential for normal fungal pathogenicity. Specifically, the inhibition of pyrroline-5-carboxylate reductase gene expression in fungi results in drastically reduced pathogenicity. Thus, pyrroline-5-carboxylate reductase can be used as a target for the identification of antibiotics, preferably antifungals. Accordingly, the present invention provides methods for the identification of compounds that inhibit pyrroline-5-carboxylate reductase expression or activity. The methods of the invention are useful for the identification of antibiotics, preferably antifungals.

Abstract translation: 本发明人已经发现吡咯啉-5-羧酸还原酶对于正常的真菌致病性是必需的。 具体地，抑制真菌中吡咯啉-5-羧酸还原酶基因的表达导致致病性急剧下降。 因此，吡咯啉-5-羧酸还原酶可用作鉴定抗生素，优选抗真菌剂的靶标。 因此，本发明提供了鉴定抑制吡咯啉-5-羧酸还原酶表达或活性的化合物的方法。 本发明的方法可用于鉴定抗生素，优选抗真菌剂。

公开(公告)号：US20040234555A1

公开(公告)日：2004-11-25

申请号：US10485368

申请日：2004-01-30

Inventor： Toshio Oshida ,  Tohru Tanaka

IPC: C12Q001/18

CPC classification number: A61K31/295 ,  A23K20/142 ,  A23K20/30 ,  A23K50/00 ,  A23K50/60 ,  A61K31/197 ,  A61K33/26 ,  A61K2300/00

Abstract: A pig growth enhancer, which comprises, as an active ingredient, at least one compound selected from 5-aminolevulinic acid, a derivative thereof and a salt thereof, and a method for enhancing pig growth, which comprises administering the growth enhancer to a pig.

Abstract translation: 一种猪生长增强剂，其包含至少一种选自5-氨基乙酰丙酸，其衍生物和其盐的化合物作为活性成分，以及增强猪生长的方法，其包括将生长增强剂施用于猪。

公开(公告)号：US20040192591A1

公开(公告)日：2004-09-30

申请号：US10722695

申请日：2003-11-24

Inventor： Joseph L. Wooters ,  Benjamin J. Metcalf ,  Banumathi Sankaran

IPC: A61K038/12 ,  C12Q001/18

CPC classification number: G01N33/56927 ,  G01N2500/00

Abstract: The invention relates to therapeutic modalities and pharmaceutical compositions for the treatment of Chlamydia-infection using cyclophilin polypeptides and its corresponding human cellular binding partner or partners as a target for intervention. The present invention relates to the use of exogenous or engrafted sources of cyclophilins, anti-cyclophilin antibodies, cyclophilin decoys, soluble forms of cyclophilin-binding partners and small molecules which are supplied extracellularly, and act presumably by interrupting the binding of cyclophilin A with its cellular binding partner(s) or receptor(s), as a treatment for Chlamydia-infection. The present invention further relates to screening assays for the identification of compounds that inhibit the interaction of cyclophilin and its Chlamydia binding partners.

Abstract translation: 本发明涉及使用亲环蛋白多肽及其相应的人细胞结合配偶体或伴侣作为干预对象来治疗衣原体感染的治疗方式和药物组合物。 本发明涉及外源或植入源的亲环蛋白，抗亲环蛋白抗体，亲环蛋白诱饵，亲环蛋白结合配偶体的可溶性形式和细胞外供体的小分子的用途，并且可能通过中断亲环蛋白A与其亲和素结合的结合 细胞结合配偶体或受体作为衣原体感染的治疗。 本发明还涉及用于鉴定抑制亲环蛋白与其衣原体结合配偶体相互作用的化合物的筛选测定。

公开(公告)号：US20040180829A1

公开(公告)日：2004-09-16

申请号：US10802425

申请日：2004-03-17

Inventor： Bonnie L. Bassler ,  Carol Dammel ,  Stephan Schauder ,  Kevan Shokat ,  Jeffrey Stein ,  Michael G. Surette

IPC: A61K038/17 ,  A61K048/00 ,  C12Q001/18

CPC classification number: C12Q1/18 ,  A61K31/00 ,  A61K31/34 ,  A61K31/365 ,  A61K31/38 ,  A61K31/385 ,  A61K31/40 ,  A61K39/00 ,  A61K45/06 ,  C07K14/28 ,  Y02A50/401 ,  Y02A50/47 ,  Y02A50/472 ,  A61K2300/00

Abstract: The invention provides autoinducer-2 analogs that regulate the activity of autoinducer-2 and methods of using such analogs for regulating bacterial growth and pathogenesis.

Abstract translation: 本发明提供了调节自体诱导剂-2的活性的自动诱导剂-2类似物和使用这种类似物调节细菌生长和发病机理的方法。

公开(公告)号：US20040126365A1

公开(公告)日：2004-07-01

申请号：US10381271

申请日：2003-09-08

Inventor： Daniel F Villamar ,  David J. W. Moriarty

IPC: A61K045/00 ,  G01N033/48 ,  G01N033/50 ,  C12Q001/18 ,  G06F019/00

CPC classification number: H04L29/06027 ,  A01K29/00 ,  C12Q1/10 ,  G01N2333/28 ,  G16H50/80 ,  H04L65/80 ,  H04L67/12 ,  Y02A90/24 ,  Y02A90/26

Abstract: A system, method and computer program product for controlling disease at an end user location, including (a) testing a range of candidates including at least one of: (i) Bacillus species, (i) Bacillus strains, (iii) species of beneficial bacteria (iv) strains of beneficial bacteria and (v) strains of beneficial bacterial viruses, against samples including at least one of pathogenic Vibrio, Gram negative pathogenic bacteria and Gram positive pathogenic bacteria taken from an end user location; (b) performing at least one of the following steps: (i) selecting one or more of the candidates that one of inhibit and attack at least one of the samples by direct inhibition of at least one of in situ antibiotic production, competitive exclusion, production of enzymes that degrade quorum sensing molecules, and (ii) testing a range of quorum sensing inhibitor compounds against the samples; and (c) performing the steps (a) and (b) for the end user location, including one of a country, major region and individual end user location, to target microbial technology to use in bio-control of disease specific to the end user location.

Abstract translation: 一种用于在最终用户位置控制疾病的系统，方法和计算机程序产品，包括（a）测试一系列候选物，包括以下中的至少一个：（i）芽孢杆菌属物种，（i）芽孢杆菌菌株，（iii）有益物种 细菌（iv）有益细菌菌株和（v）有益细菌病毒菌株，对来自最终用户位置的致病弧菌，革兰氏阴性病原菌和革兰氏阳性病原菌中的至少一种的样品; （b）执行以下步骤中的至少一个：（i）通过直接抑制至少一种原位抗生素生产，竞争性排除，选择一种或多种候选，选择一种抑制和攻击至少一种样品的样品， 产生降解群体感应分子的酶，和（ii）针对样品测试一系列群体感应抑制剂化合物; （c）为包括国家，主要地区和个人最终用户位置之一的最终用户位置执行步骤（a）和（b），以将微生物技术用于生物控制特定于疾病的疾病的生物控制 用户位置。

公开(公告)号：US20040115756A1

公开(公告)日：2004-06-17

申请号：US10387788

申请日：2003-03-13

Inventor： Jennifer A. Black ,  Ellen A. Smith Moland ,  Kenneth S. Thomson

IPC: C12Q001/18

CPC classification number: C12Q1/34 ,  C12Q1/18

Abstract: The present invention provides a method of determining the antibiotic susceptibility of a microorganism comprising the following steps. First, a culture of the microorganism whose susceptibility is to be determined is admixed with an antibiotic to which susceptibility is to be assayed, and a permeabilizing agent for the microorganism present in a non-growth-inhibiting microorganism-permeabilizing effective amount to form an assay culture. Next, the assay culture is incubated under appropriate culture conditions and for a time sufficient to determine the susceptibility of the microorganism to the antibiotic. In another aspect, the present invention provides an improved method for antibiotic susceptibility testing of a microorganism in a culture by admixing the culture with an antibiotic to which susceptibility is to be assayed, and incubating the culture for a time sufficient to determine the susceptibility of the microorganism to the antibiotic, the improvement comprising admixing the culture with a permeabilizing agent for the microorganism present in a non-growth inhibiting microorganism-permeabilizing effective amount.

Abstract translation: 本发明提供了确定微生物的抗生素敏感性的方法，包括以下步骤。 首先，将要测定其易感性的微生物的培养物与要测定易感性的抗生素混合，以及存在于非生长抑制性微生物透化有效量的微生物渗透剂以形成测定 文化。 接下来，将测定培养物在合适的培养条件下温育足以确定微生物对抗生素的敏感性的时间。 另一方面，本发明提供了一种用于通过将培养物与待测定易感性的抗生素混合培养的培养物中的微生物的抗生素敏感性测试的改进方法，并将培养物温育足以确定培养物的易感性 微生物对抗生素的改善，其包括将培养物与以非生长抑制性微生物渗透有效量存在的微生物渗透剂混合。

公开(公告)号：US20040086844A1

公开(公告)日：2004-05-06

申请号：US10285800

申请日：2002-10-31

Inventor： John Stephen Dunfield ,  Ronnie J. Yenchik

IPC: C12Q001/18 ,  C12M001/34

CPC classification number: C12M29/06

Abstract: A culture device for cellular media including a biomedia growth chamber defining a closed environment and an electronically controllable jetting device in communication with a source of material supporting biological function. The jetting device emits the material into the biomedia growth chamber.

Abstract translation: 一种用于细胞培养基的培养装置，包括限定封闭环境的生物培养基生长室和与支持生物功能的材料源连通的电子可控喷射装置。 喷射装置将材料发射到生物培养基生长室中。

公开(公告)号：US20040018582A1

公开(公告)日：2004-01-29

申请号：US10223130

申请日：2003-04-15

Inventor： Ulrike Eggert ,  Natividad Ruiz ,  Brian Falcone ,  Arthur Branstrom ,  Robert Goldman ,  Thomas Silhavy ,  Daniel Kahne

IPC: C12Q001/18

CPC classification number: C12Q1/48 ,  C12Q1/18 ,  G01N2500/10

Abstract: The present invention relates to methods for identifying antibiotic compounds having transglycosylase inhibitory activity or transpeptidation inhibitory activity.

Abstract translation: 本发明涉及用于鉴定具有转糖基酶抑制活性或转肽抑制活性的抗生素化合物的方法。